Our lead clinical candidate is VIAject™, a very rapid-acting form of injectable human insulin for meal-time use by patients with Type 1 or Type 2 diabetes. VIAject™ is comprised of commercially available recombinant human insulin and our proprietary formulation of ingredients, all of which are Generally Regarded As Safe (GRAS) by the FDA. Our proprietary formulation delivers insulin in a form which more closely resembles the way a normal body uses insulin to help glucose enter the body's cells, providing energy that allows the body to function. Currently, insulin therapies are not delivered quickly enough to simulate the desired meal-time insulin spike. In tests to date, the VIAject™ formulation of insulin promotes a more rapid absorption, which more closely mirrors the effects of naturally produced insulin in non-diabetics thereby providing more effective blood glucose control. This novel therapy is currently undergoing two pivotal Phase III clinical studies. The two studies, one involving 400 patients with Type 1 diabetes and the other involving 400 patients with Type 2 diabetes, are comparing the effects of VIAject™ to Humulin®, the leading recombinant human insulin.
The graph below from our clinical trials shows that VIAject™ is absorbed by the body markedly faster than Humulin®, and does not linger in the blood as long as Humulin®, thereby reducing a diabetic's risk of hyperglycemia and hypoglycemia.
We believe the advantages of VIAject™ are: